To determine the risk of developing obesity and related metabolic complications in children following long-term treatment with risperidone or quetiapine.
D uring the last 2 decades, prescriptions of atypical or SGAs to children and adolescents have increased significantly. [1] [2] [3] From 1996 to 2011, SGA prescriptions in BC increased from 0.33/1000 children (<19 years old) to 5.98/1000 children, with risperidone and quetiapine the most commonly used SGAs in this population. 3 During this time period, there has also been a growing body of literature demonstrating an increased risk of metabolic complications in children treated with SGAs, including weight gain, dyslipidemia, insulin resistance, and type 2 DM. [4] [5] [6] [7] [8] [9] [10] [11] Despite our knowledge of these side effects, monitoring rates for metabolic complications during SGA treatment have historically been very low. 12, 13 A recent retrospective analysis of metabolic monitoring in 1023 children treated with SGAs in the United States showed that only 0.1% received all baseline metabolic monitoring, with fasting glucose measured in 8.2% and lipid panel measured in 7.1% at baseline. 13 In our tertiary care centre in the child and adolescent psychiatric emergency unit, a retrospective chart review demonstrated that only 34% of children treated with SGAs had a fasting glucose measured and only 32% had a lipid panel measured. 14 These low monitoring rates are of utmost concern, given that, if left untreated, these side effects pose an increased risk for serious cardiovascular complications and increased mortality in adulthood. 15 Previous retrospective studies have demonstrated that longterm SGA treatment in children is common. 10, 16 In fact, Baeza et al 16 reviewed SGA use in 265 children, 17 years of age and younger, and, at 12 months following the initiation of SGA treatment, 41% of study participants continued to be treated with an SGA. We have previously evaluated metabolic side effects in children treated with SGAs and found a median treatment duration of 7 months, with a range of treatment duration of up to 84 months. Prospective studies clearly suggest that SGAs confer increased risk for development of weight gain and dyslipidemia over the short term (<3 months). 17 Although long-term SGA use in children is a common practice, investigation of metabolic complications over the long term is limited to retrospective reports. 10, [18] [19] [20] Thus we conducted a prospective longitudinal study to assess the impact of the 2 most commonly used SGAs, risperidone and quetiapine, on weight gain and the development of metabolic complications during the first 12 months of treatment. We hypothesized that children previously naive to SGAs would have a higher incidence of obesity, central adiposity, and elevated fasting glucose and 
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Clinical Implications
• This is the first prospective long-term study describing metabolic complications in SGA-treated children.
Our study confirms the significant metabolic effects of risperidone and quetiapine in children with mental illness during 1 year of treatment.
• Routine monitoring to identify metabolic complications early in treatment is necessary and should be implemented as soon as SGA treatment is initiated.
• Prospective studies with larger sample sizes and a longer follow-up period should be conducted to investigate the long-term metabolic effects of SGA treatment.
Limitations
• The most notable limitation to our study is our small sample size, mainly owing to poor adherence to metabolic monitoring.
• Our study lacked a control group with which to compare the observed changes in patients who were treated with SGAs with metabolic parameters during the 12-month time period. 
Methods
Study Design
The study design was a 1-year naturalistic prospective longitudinal study. The study was reviewed and approved by both the University of British Columbia Clinical Research Ethics Boards and the Children's and Women's Hospital Research Review Committee. Written informed consent was obtained from parents or legal guardians of all participating children. Written informed assent was also obtained from children when possible, depending on developmental level and capability.
Children cared for at one of the child and adolescent psychiatry outpatient clinics in BC were invited to participate in the study between February 2009 and March 2012. Study participants were selected based on the following inclusion criteria: 2 to 18 years of age; having a mental health condition diagnosed based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision; SGA treatment with either risperidone or quetiapine independently initiated by a psychiatrist less than 7 days before study consent; and never previously exposed to an SGA. Exclusion criteria included pre-existing DM (types 1 or 2), diagnosis of an eating disorder, treatment with more than 1 antipsychotic, or treatment with other medications known to affect metabolism (for example, glucocorticoids).
Data Collection
Data collection was based on an evidence-based clinical tool for metabolic monitoring with SGA treatment, previously implemented at child and youth mental health teams in BC. The collected data included patient history (psychiatric diagnosis, age, sex, ethnic background, family history of type 2 DM, and other cardiovascular risk factors), physical examination (for example, height, weight, blood pressure, and WC), and biochemical assessment (for example, fasting glucose, insulin, and lipid profile).
Diagnostic Criteria
BMI was calculated [weight (kg)/height squared (m 2 )], and standardized for age and sex (BMI z score). 21 Obesity was defined as BMI z score greater than or equal to the 95th percentile and overweight as BMI z score between the 85th and the 95th percentile. 22 WC was measured in centimetres and categorized as 90th or more (high WC) or less than 90th percentile for sex and age. 23 Hypertension was defined as having either an SBP or DBP of 95th percentile or more for age, sex, and height. Prehypertension was defined as having SBP or DBP of 90th or more and less than the 95th percentile. 24 Presence of IR was estimated using the HOMA-IR [glucose (mmol/L) × insulin (mU/L)/22.5]. 25 IR was defined as HOMA-IR of more than 4.39. 26 Hypercholesterolemia was defined as a level of total cholesterol 4.4 mmol/L or more. The thresholds for high LDL cholesterol and low HDL cholesterol were 2.85 mmol/L or more and 1.03 mmol/L or less, respectively. 27
Statistical Analysis
Statistical analysis was performed on all available data from subjects who completed 12 months of SGA treatment, even if data collection at that time point was incomplete. Baseline data are reported as medians (95% CIs) for continuous variables, and as frequencies and percentages for categorical variables. To assess the differences between the subject populations receiving each medication prior to the start of SGA treatment, baseline data were compared across SGA treatment groups (risperidone, compared with quetiapine) using the chi-square and Fisher exact tests for categorical variables and the Kruskal-Wallis test for continuous variables. Given that not all of the continuous variables in the data set were normally distributed, we used the Kruskal-Wallis test as a nonparametric test, which is more flexible and does not assume a normal distribution of the residuals. Changes to continuous variables over time were assessed, in each treatment group, using the linear mixed model. The time factor for the model was set at baseline and months 6 and 12. Post hoc marginal pairwise comparisons were performed to create the adjusted means (95% CIs) of changes of each continuous variable from baseline to 12 months. Incidence was calculated based on the proportion of new-onset metabolic outcomes identified in at least 1 follow-up visit divided by the number of subjects having data available. All the analyses were performed on Stata version 12.1 (StataCorp LP, College Station, TX).
A P value of less than 0.05 was considered statistically significant.
Results
From February 1, 2009, through to March 31, 2012, 130 eligible subjects who were treated with SGAs were recruited for, and entered into, our study. Among these, 62 were treated with risperidone (53.9%) and 53 were treated with quetiapine (46.1%). Thirty-seven of the 130 subjects (28.5%) treated with risperidone or quetiapine completed 12-month monitoring and were included in the analysis (Figure 1 ).
The baseline demographic and clinical characteristics are presented in Table 1 . Subjects ranged in age from 4 through to 18 years, with an equal proportion of male and female subjects among those who completed 12 months of SGA treatment with comprehensive metabolic monitoring. There was no difference in the proportion of Caucasian, compared with non-Caucasian, ethnicities between risperidone-and quetiapine-treated subjects. There were also no differences in baseline anthropometric measurements or biochemical parameters between the 2 groups.
Changes to anthropometric measurements are presented in Table 2 . After 12 months of SGA treatment, subjects had a mean weight increase of 10.8 kg (95% CI 7.9 kg to 13.7 kg, P < 0.001) with risperidone and 9.7 kg (95% CI 6.5 kg to 12.8 kg, P < 0.001) with quetiapine. In both risperidone-and quetiapine-treated subjects, the BMI z score significantly increased (P < 0.001). Subjects also had a significant WC increase over time of 11.5 cm (95% CI 8. Changes to biochemical parameters during 12 months of SGA treatment are presented in Table 3 . When analyzed as one group (risperidone + quetiapine), there was a significant increase in all biochemical parameters (fasting glucose, fasting insulin, HOMA-IR, triglycerides, ratio of triglycerides to HDL cholesterol, and ratio of total Patients with mental health conditions approached by research team, n = 174 Excluded before or during consenting process, n = 27: eating disorder, n = 1 previous SGA use, n = 5 SGA not started, n = 8 genetic disease, n = 1 declined, n = 12
Excluded, n = 17: eating disorder, n = 4 hypothyroidism, n = 2 genetic disease, n = 2 previous SGA use, n = 1 SGA not started, n = 8
Excluded, n = 77: incomplete baseline data, n = 6 moved out of BC, n = 6 noncompliant SGA treatment, n = 6 stopped SGA before 3 months, n = 28 stopped SGA before 6 months, n = 13 monitoring not done, n = 15 switched SGA treatment, n = 2 stopped SGA owing to side effect, n = 1
Excluded, n = 8: received aripiprazole, n = 1 received ziprasidone, n = 1 received olanzapine, n = 4 received both risperidone and quetiapine, n = 2
Patients who consented, n = 147
Patients who entered the study, n = 130
Patients who completed 6-month monitoring, n = 53 cholesterol to HDL cholesterol). However, after stratification by treatment group, a significant increase was only found in fasting glucose in risperidone-treated subjects and the ratio of total cholesterol to HDL cholesterol in quetiapine-treated subjects.
New metabolic complications after 12 months of SGA treatment are presented in 
Discussion
To our knowledge, this is the first prospective long-term study describing metabolic complications in children treated with SGAs. The results confirm that children receiving 12 months of treatment with risperidone or quetiapine have a high incidence of becoming overweight or obese. In comparison with a previous short-term cohort study evaluating metabolic complications during a mean duration of 10.8 weeks of treatment, 17 the higher incidence of overweight and obesity observed in our study (40%, compared with 14.1% for risperidone, and 50%, compared with 36.1% for quetiapine) suggests that the metabolic complications in children treated with SGAs worsen with longer treatment duration. Our study clearly demonstrates weight gain early in SGA treatment, with continued increase in weight during the first year of treatment. This is of particular concern given that, when compared with the general population, obese children have more than double the risk of developing DM, hypertension, and cardiovascular disease in adulthood. 28 Even more alarming than the development of obesity is that our study subjects had a significant increase in WC, a more sensitive and specific predictor of metabolic syndrome, 10 with nearly one-quarter of the subjects transitioning to elevated WC after 12 months of SGA treatment. In fact, the mean increase in WC observed during 12 months in our study is comparable with that seen in adult studies where subjects were treated with risperidone, olanzapine, or quetiapine for 1 year. 29 Further, metabolic dysregulation in childhood is known to result in a higher risk for adverse cardiovascular complications in adulthood. 30, 31 This further emphasizes the importance of regular metabolic monitoring during SGA treatment to mitigate these complications at their onset.
While changes to body composition were significant during both the 6-and 12-month time points in both groups, changes to most of the lipid parameters reached significance only at the 6-month time point. Specifically, subjects were found to have significant increases in total cholesterol, LDL cholesterol, and significant decreases in HDL cholesterol during the first 6 months of treatment. This is consistent with a study in children published by Correll et al 17 where lipid profile abnormalities were seen within 3 months of SGA treatment. By the 12-month time point, only the ratio of total cholesterol to HDL cholesterol showed a statistically significant increase from baseline (Table 3 ). We suspect that this is not likely indicative of dyslipidemia improving over time with SGA treatment, but rather a reflection of factors, such as inherent variability of laboratory assays and the small sample size. Further, hypertriglyceridemia and the ratio of triglycerides to HDL cholesterol were both found to increase at the 12-month time period. While outside the scope of the data collected for our study, we suspect that some study subjects may have received dietary and physical activity interventions following the development of dyslipidemia, which may have impacted the trajectory of these metabolic complications. Nevertheless, it remains concerning that there was a high incidence of new-onset dyslipidemia within 6 months of SGA treatment, given its strong association with long-term cardiovascular risk, 32 and therefore warrants ongoing longer-term study in a larger cohort.
Similar to lipid parameters, glucose homeostasis changes were observed at multiple time points. Changes to glucose homeostasis were observed at 6 months and continued to worsen by 12 months. While no new cases of type 2 DM were identified in our population, our study was limited by its small sample size and we suspect that with larger numbers, type 2 DM may have been identified. In fact, Bobo et al 11 found that in 28 858 new users of antipsychotics there was a 3-fold increased risk for type 2 DM within the first year of treatment. When the latter cohort was restricted to children aged 6 to 17 years, there was more than a 3-fold increased risk of type 2 DM.
Note, comparisons between risperidone and quetiapine groups showed no significant difference in terms of change over time in metabolic indices (data not shown). However, this result should be cautiously interpreted, given the small sample size.
Strengths and Limitations
The results of our study should be interpreted within its limitations. The most notable limitation is our small sample size. Despite our best efforts to recruit a larger sample size, 2 of the main factors that limited the number of subjects with 12-month data available for analysis were poor adherence to metabolic monitoring and discontinuation of SGA treatment prior to 12 months. Nevertheless, we feel it is extremely important to publish our experience, including our challenges to assist other researchers in planning feasible prospective studies with a larger sample size.
While understanding the factors impacting adherence to SGA treatment and metabolic monitoring in children is important for clinical care, exploring these variables was outside the scope of our study. However, we did compare 37 included subjects to 93 excluded subjects and found no statistically significant differences in any baseline characteristics. Further, we did not document a significant change in SBP or DBP z scores after 12 months of monitoring. This is likely owing to the 2 following factors: lack of power with our small sample size, and (or) monitoring time being too short to detect this change. Nevertheless, this is the first prospective study reporting longitudinal metabolic complications, including significant weight gain, elevated WC, and dyslipidemia, in children treated for 1 year with risperidone or quetiapine.
Conclusion
Our study demonstrates that children treated with either risperidone or quetiapine have a high risk of becoming overweight or obese and developing a high WC over the initial 12-month treatment period. These findings highlight the importance of considering the risks of these medications in the context of potential benefit when making treatment decisions. Further, these data highlight the importance of regular metabolic monitoring during SGA treatment to identify and treat metabolic dysregulation as early as possible. Future studies are needed to evaluate SGA treatment in larger sample sizes over the long term to further assess the pattern of onset and risk for metabolic complications.
Clinical Significance
Our prospective longitudinal study confirms the significant metabolic effects of risperidone and quetiapine in children with mental illness during 1 year of treatment. Routine monitoring to identify metabolic complications early in treatment is necessary and should be implemented as soon as SGA treatment is initiated. Prospective studies with larger sample sizes and a longer follow-up period should be conducted to investigate long-term effects of SGA treatment on lipid abnormalities and glucose homeostasis.
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